Table 1 Characteristics of Discovery and Validation cohorts
| Â | Discovery cohort | Validation cohort | ||
|---|---|---|---|---|
PwHCC (N = 55) | Healthy participants (N = 55) | PwHCC (N = 54) | Healthy participants (N = 55) | |
N (%) | N (%) | N (%) | N (%) | |
Gendera | ||||
 Female | 8 (14.5) | 32 (58.2) | 16 (29.6) | 29 (54.7) |
 Male | 47 (85.5) | 23 (41.8) | 38 (70.4) | 24 (45.3) |
Ageb | ||||
 Median | 58 | 42 | 60 | 40 |
 Min | 24 | 25 | 33 | 26 |
 Max | 87 | 81 | 77 | 67 |
Stage | ||||
 I | 9 (16.4) | NA | All patients were confirmed to have non-metastatic HCC | NA |
 II | 29 (52.7) | NA | NA | |
 III | 3 (5.5) | NA | NA | |
 NA | 14 (25.5) | NA | NA | |
Risk factor | ||||
 HBV | 43 (78.2) | NA | 32 | NA |
 HCV | 3 (5.5) | NA | 10 |  |
 HBV/HCV | 1 (1.8) | NA | 1 |  |
 No | 6 (10.9) | NA | 7 |  |
 Not detected | 2 (3.6) | NA | 3 |  |